TB-500 (Thymosin Beta-4)

TB-500 is a synthetic peptide modeled (also spelled modeled) on the active region of Thymosin Beta-4 (TB4), a naturally occurring 43-amino-acid polypeptide encoded by the TMSB4X gene. ^(1,2) TB4 was first isolated from calf thymus tissue by Allan Goldstein and colleagues and is recognized (also spelled recognized) as the primary intracellular G-actin sequestering molecule in mammalian cells. ^(1,2) TB4 is expressed in high concentrations across virtually all tissue types, with particularly high levels in blood platelets, white blood cells, wound fluid, and developing embryonic tissue, which signals its fundamental role in tissue repair and cellular organization. ^(1,2)

The biological activity of TB4 is determined by specific regions within its 43-amino-acid sequence. The actin-binding domain, centered on the seven-amino-acid LKKTETQ motif, is essential for TB4’s angiogenic, cell-migratory, and wound-healing activities. ^(1,3) Research by Grant et al. demonstrated that this actin-binding motif displays near-identical angiogenic activity to full-length TB4 at approximately 50 nanomolar concentration, while peptides lacking any portion of this motif lose activity entirely. ⁽³⁾ TB-500, as a research product, contains this critical active region.

TB-500 has a well-documented history in veterinary medicine, particularly for the treatment of equine soft tissue injuries, including tendon, ligament, and muscle damage. ^(1,2) This veterinary application provided much of the early practical evidence for TB-500’s tissue repair capabilities and contributed to its inclusion on the World Anti-Doping Agency’s (WADA) prohibited list for both human and equine sports. ⁽⁶⁾

TB-500 is not FDA-approved for any human therapeutic indication. In September 2023, Thymosin Beta-4 (and, by extension, TB-500) was classified as an FDA Category 2 bulk drug substance, restricting compounding pharmacies from preparing it for patients. ⁽⁵⁾ A potential reclassification was announced in February 2026 but had not been formally published as of March 2026. ⁽⁵⁾ WADA prohibits TB-500 under S0 (Non-Approved Substances) and S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) provisions. ⁽⁶⁾ Healius supplies TB-500 as a lyophilized (also referred to as lyophilized) powder in 10mg vials, intended strictly for laboratory and research applications.

TB-500’s mechanism of action centers on its role as a G-actin sequestering molecule, a function that is foundational to understanding its downstream biological effects. ^(1,2,3)

Actin is one of the most abundant proteins in eukaryotic cells and exists in two forms: G-actin (globular, monomeric) and F-actin (filamentous, polymerized). The dynamic assembly and disassembly of actin filaments drive cell migration, cell division, wound contraction, and tissue remodeling. ^(1,2) TB-500 regulates the intracellular pool of G-actin available for filament assembly. By sequestering G-actin monomers, TB-500 controls the rate and location of actin polymerization (also spelled polymerization), effectively directing where and how fast cells move. ^(1,2)

This actin regulation underlies TB-500’s primary research applications. Cell migration is the most direct consequence: TB-500 stimulates keratinocyte migration (2-3-fold increase in Boyden chamber assays with as little as 10 picograms), endothelial cell migration, and fibroblast migration to wound sites. ^(3,4) Angiogenesis (new blood vessel formation) requires endothelial cells to migrate and form tubular structures. TB-500 promotes endothelial cell migration, adhesion, and tubule formation, with the seven-amino-acid actin-binding motif identified as essential for this activity. ⁽³⁾

TB-500 also influences multiple intracellular signaling cascades beyond its direct actin-binding effects. The PI3K/AKT/mTOR pathway promotes cell survival and proliferation. The MAPK/ERK pathway supports cell differentiation and growth-factor responses. The Notch/NF-κB pathway modulates angiogenesis and inflammation. ^(1,2) TB-500 also forms complexes with PINCH and integrin-linked kinase (ILK), activating downstream survival signaling. ⁽¹⁾ These diverse pathway interactions explain why TB-500 produces effects across multiple tissue types and biological processes.

TB-500 research spans wound healing, cardiac tissue repair, corneal healing, neurological recovery, and hair follicle development, with published data primarily from preclinical models. ^(1,2,3,4)

Wound healing is the most extensively documented application. Malinda et al. demonstrated that topical or intraperitoneal administration of TB4 increased re-epithelialization by 42% over saline controls at 4 days and by as much as 61% at 7 days post-wounding in a rat full-thickness wound model. ⁽⁴⁾ Treated wounds also contracted at least 11% more than controls by day 7, with increased collagen deposition and angiogenesis observed. ⁽⁴⁾ In diabetic mice (db/db model), TB4 in hydrogel or phosphate-buffered saline significantly accelerated wound healing compared to untreated controls, with relevance to the clinical challenge of impaired wound healing in diabetic patients. ⁽¹⁾ After 14 days, collagen fiber bundles in treated groups were thicker and longer, with reduced scarring. ⁽¹⁾

Cardiac repair research has demonstrated that TB4 reduces necrotic areas following myocardial infarction, increases survival rates, upregulates VEGF expression and superoxide dismutase activity, and reduces malondialdehyde levels (an oxidative stress marker). ⁽²⁾ A pilot human study by Zhu et al.  ⁽²⁰¹⁶⁾ examined autologous TB4-pretreated endothelial progenitor cell transplantation in patients with acute ST-segment elevation myocardial infarction, representing one of the few direct human applications of TB4-related therapy. ⁽¹⁾

Corneal wound-healing research by Sosne et al. demonstrated that TB4 is an effective corneal wound-healing and anti-inflammatory agent, suppressing NF-kB activation in corneal tissue. ⁽¹⁾ Neurological research by Zhang et al. showed recovery of neurological function in mice with experimental autoimmune encephalomyelitis following TB4 treatment. ⁽¹⁾ Hair follicle development is another documented effect: TB4 promotes angiogenesis at the follicular level and stimulates hair growth in preclinical models. ^(2,3)

A 2025 review in a PMC orthopedic journal positioned TB-500 alongside BPC-157 and GHK-Cu as wound-healing therapeutic peptides with applications in musculoskeletal rehabilitation, noting its role in promoting actin polymerization, progenitor cell recruitment, and enhanced cellular migration. ⁽⁷⁾

The combination of TB-500 with BPC-157 is the most widely discussed multi-peptide regenerative protocol, driving enormous search volume (“bpc 157 and tb 500” alone exceeds 2,900 US monthly searches). ^(7,8)

The synergy rationale is mechanistically well-defined: BPC-157 operates primarily through VEGFR2/nitric oxide/FAK-paxillin pathways to promote vascular repair and cytoprotection, while TB-500 operates through actin sequestration/PI3K-AKT/MAPK pathways to promote cell migration and tissue remodeling. ^(7,8) These are complementary rather than overlapping mechanisms: BPC-157 establishes the vascular infrastructure and reduces inflammation, while TB-500 mobilizes the repair cells needed to rebuild the damaged tissue.

The practical implication: using both compounds simultaneously addresses more layers of the repair cascade than either compound alone. BPC-157 restores blood supply and creates a protective anti-inflammatory environment. TB-500 drives the cellular migration, collagen deposition, and structural reorganization required for tissue rebuilding. A 2025 GlobalRPH review specifically evaluated BPC-157 and TB-500 together, noting their “pleiotropic effects on wound healing, angiogenesis, tissue regeneration, and inflammatory modulation.” ⁽⁸⁾

Healius offers both compounds individually and as a pre-combined BPC-157 + TB-500 Blend for researchers who prefer a single-vial formulation. For the three-peptide regenerative formula that adds GHK-Cu to the BPC-157/TB-500 base, see our Glow Peptide. For the four-peptide formula that further adds KPV anti-inflammatory support, see our Klow Peptide.

The “TB-500 vs BPC-157” comparison is among the highest-volume peptide comparison queries, and while the two compounds are most commonly used together, understanding their individual strengths helps researchers design targeted protocols. ^(7,8)

BPC-157 excels at vascular repair (angiogenesis via VEGFR2 upregulation), gastrointestinal protection (200+ preclinical GI studies), and systemic cytoprotection (nitric oxide modulation and growth factor signaling). It is primarily a “repair the environment” peptide: it restores blood supply, modulates inflammation, and protects existing tissue from further damage. ⁽⁸⁾

TB-500 excels at cellular mobilization (actin-driven cell migration to wound sites), structural tissue rebuilding (collagen deposition, re-epithelialization), and anti-scarring effects (reduced myofibroblast numbers). It is primarily a “rebuild the structure” peptide: it moves repair cells where they are needed and directs the physical reconstruction of damaged tissue. ^(1,2,4)

For researchers focused on gut health, GI protection, or vascular integrity, BPC-157 is the primary compound. For researchers focused on musculoskeletal repair, wound closure, or post-surgical tissue remodeling, TB-500 is the primary compound. For comprehensive regenerative protocols that address both vascular environment and structural repair, the combination is standard. Healius offers individual BPC-157 and TB-500, the pre-combined BPC-157 + TB-500 Blend, and extended blends, including the Glow Peptide and Klow Peptide.

1. Innerbody. TB4 and TB-500 Peptide Therapy: What to Know in 2026. Comprehensive review: Tβ4 biology, TMSB4X gene, actin binding, tissue distribution, veterinary use, human pilot study (Zhu 2016), wound healing, and neurological recovery.

2. Xing Y et al. Progress on the Function and Application of Thymosin β4. Front Endocrinol (Lausanne). 2021; 12:767785. PMC8724243. Comprehensive review: 43 amino acids, active domains (aa 1-4 anti-inflammatory, aa 1-15 anti-apoptotic, aa 17-23 angiogenic/hair growth), cardiac repair, wound healing, anti-fibrotic effects.

3. Grant DS et al. The actin-binding site on thymosin beta4 promotes angiogenesis. FASEB J. 2003. The LKKTETQ motif is essential for angiogenic activity at ~50 nM. Endothelial cell migration: 2-3-fold increase. PMID: 14500546.

4. Malinda KM et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-368. PMID: 10469335. 42% re-epithelialisation at 4 days, 61% at 7 days, 11% more contraction, increased collagen, and angiogenesis.

5. FDA Category 2 Bulk Drug Substances. September 2023. Thymosin Beta-4/TB-500 classified as Category 2—potential reclassification announced in February 2026.

6. WADA Prohibited List 2026. Thymosin Beta-4 is prohibited under S0 (Non-Approved Substances) and S2 provisions at all times.

7. PMC12753158. Therapeutic Peptides in Orthopedics: Applications, Challenges, and Future Directions. 2025. TB-500 alongside BPC-157 and GHK-Cu as wound-healing peptides. Actin polymerization, progenitor cell recruitment, and cellular migration.

8. GlobalRPH. BPC-157 and TB-500: Background, Indications, Efficacy, and Safety. 2025. Combined review: pleiotropic effects on wound healing, angiogenesis, tissue regeneration, and inflammatory modulation.

This product is sold strictly for laboratory and research use only. It is not intended for human or animal consumption. It is not a dietary supplement, food, drug, or cosmetic. It is not intended to diagnose, treat, cure, or prevent any disease or condition. The buyer assumes all responsibility for the lawful use of this product in accordance with all applicable local, state, national, and international laws and regulations. By purchasing this product, the buyer confirms that they are a qualified researcher or are purchasing on behalf of a research institution.